Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

Key Points

• The analysis aims to evaluate and compare the safety profiles of SGLT2 and DPP4 inhibitors in patients diagnosed with type 2 diabetes.
• Systematic review following PRISMA guidelines
• Meta-analysis of randomized controlled trials
• Prospectively registered protocol
• SGLT2 inhibitors show a favorable safety profile compared to DPP4 inhibitors.
• The majority of adverse events reported were mild to moderate.